Venezuela extends comment period for draft biosimilars guidance
This article was originally published in Scrip
Companies wishing to comment on the draft Venezuelan biosimilars guidance now have more time to do so, after the authorities extended the consultation period from mid-December to 28 February 2014. As well as explaining the preclinical and clinical requirements of the comparability exercise, the guidance allows for the extrapolation of indications provided certain criteria are met.
You may also be interested in...
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.
The EU’s new health commissioner, Stella Kyriakides, has outlined the commission’s plans for dealing with medicines access issues in the EU member states. They include completing the review of the EU pediatric and orphan legislation and developing a new strategic plan to tackle shortages and affordability problems next year.
AstraZeneca’s Lynparza can now be used on the Scottish National Health Service for newly diagnosed advanced ovarian cancer.